{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:26:23Z","timestamp":1790115983268,"version":"4.0.1"},"reference-count":64,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung cancer is a leading cause of cancer-related deaths, with Non-Small Cell Lung Cancer (NSCLC) comprising 85\u201390% of cases, most commonly adenocarcinoma. Key mutations include EGFR Exon 19 deletions and Exon 21 L858R. While third-generation TKIs like osimertinib, lazertinib, and aumolertinib are effective, resistance often arises. Amivantamab, a bispecific monoclonal antibody targeting EGFR and c-MET, shows promise, particularly against EGFR Exon 20 insertions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To provide a comprehensive evaluation of the adverse effects associated with amivantamab in EGFR-mutant NSCLC, including their underlying pathophysiological mechanisms and evidence-based management strategies. In addition, this review aims to contextualize the clinical relevance of amivantamab by briefly outlining the therapeutic evolution of EGFR-targeted treatments, highlighting the rationale for its development, and current positioning in treatment paradigms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive review of clinical trials, including CHRYSALIS, PAPILLON, MARIPOSA, and PALOMA-III, was conducted to assess the safety and efficacy of amivantamab. Practical and early insights into managing adverse effects of amivantamab are critical to better adherence and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Adverse effects were observed in most of the patients treated with amivantamab. Common side effects included cutaneous toxicities, diarrhea, infusion-related reactions (IRRs), vascular thrombosis and pneumonitis. The most frequent cutaneous side effects were rash, paronychia, pruritis, and stomatitis. Diarrhea occurred in patients primarily due to EGFR inhibition. IRRs were predominantly mild to moderate, occurring mainly during the first cycle. Thrombosis was a notable adverse effect observed, even in patients receiving anticoagulant prophylaxis. Pneumonitis was less common but severe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management<\/jats:title>\n                    <jats:p>Adverse effects of amivantamab are managed based on severity. Cutaneous toxicities are treated with antibiotics, topical steroids, and dose adjustments. Diarrhea is managed with hydration, loperamide, and dose interruption. Infusion-related reactions (IRRs) are treated symptomatically, with epinephrine in severe cases. Anticoagulants are used for deep vein thrombosis or thromboembolism, and fibrinolytics or thrombectomy may be considered. Pneumonitis is managed by discontinuing amivantamab and using glucocorticoids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Amivantamab is effective for EGFR mutant NSCLC but can cause adverse effects. Understanding these effects and implementing management strategies can optimize outcomes, maintaining treatment efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251358871","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:20:01Z","timestamp":1752567601000},"page":"93-109","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive management strategies for amivantamab-induced toxicities and review of the literature"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1944-0861","authenticated-orcid":false,"given":"Furkan","family":"Ceylan","sequence":"first","affiliation":[{"name":"Ankara City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3488-0283","authenticated-orcid":false,"given":"Gamze","family":"Sonmez","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hacettepe University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6224-945X","authenticated-orcid":false,"given":"Ates Kutay","family":"Tenekeci","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hacettepe University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7156-344X","authenticated-orcid":false,"given":"Ahmet Arda","family":"Unal","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hacettepe University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-6139","authenticated-orcid":false,"given":"Mehmet Ali Nahit","family":"Sendur","sequence":"additional","affiliation":[{"name":"Ankara City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.4274\/tmsj.galenos.2024.2024-5-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2407280"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107414"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12651"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.10.020"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.019"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0038-9"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.2174\/1871520622666220523145609"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.11.004"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909530"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70184-X"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30634-5"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30035-X"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02911"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.456"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30033-X"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30608-3"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02641"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00515"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00662"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02554-7"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306441"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0923"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.117"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306441"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.541"},{"key":"e_1_3_2_33_2","article-title":"Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial","author":"Leighl NB","year":"2024","unstructured":"Leighl NB, Akamatsu H, Lim SM, et al. Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. J Clin Oncol 2024: LBA8505\u2013LBA8505.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8516"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30154-5"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00662"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9137"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1554"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9050052"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120082"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11340"},{"key":"e_1_3_2_42_2","first-page":"3639","article-title":"Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition","volume":"23","author":"Yano S","year":"2003","unstructured":"Yano S, Kondo K, Yamaguchi M, et al. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 2003; 23: 3639\u20133650.","journal-title":"Anticancer Res"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07685-5"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.804212"},{"key":"e_1_3_2_45_2","first-page":"1522","article-title":"EGFR Inhibitor gefitinib regulates barrier function in human epidermal keratinocytes via the modulation of the expression of claudins","volume":"43","author":"Fang H","year":"2019","unstructured":"Fang H, Wang Y, Xu L, et al. EGFR Inhibitor gefitinib regulates barrier function in human epidermal keratinocytes via the modulation of the expression of claudins. Int J Mol Med 2019; 43: 1522\u20131530.","journal-title":"Int J Mol Med"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxres\/tfab026"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e32835ec861"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.6.803"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126444"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0702"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.01.003"},{"key":"e_1_3_2_52_2","first-page":"4902","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis, blood","volume":"111","author":"Khorana AA","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis, blood. J Am Soc Hematol 2008; 111: 4902\u20134907.","journal-title":"J Am Soc Hematol"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34937"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4827(91)90078-9"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14697"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0434-6"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70006-3"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0923"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.117"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020792"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.09.012"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102922"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100404"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251358871","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251358871","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251358871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:31:28Z","timestamp":1777689088000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251358871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/10781552251358871"],"URL":"https:\/\/doi.org\/10.1177\/10781552251358871","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}